Felix Calderon
GlaxoSmithKline R&D
Tres Cantos, MD, Spain
Tres Cantos, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Identification of novel compounds with prophylactic activity against hypnozoites using a Plasmodium cynomolgi in vitro model.
Journal: Antimicrobial agents and chemotherapy
Published: July 17, 2025
Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 (TcBDF2) using a fluorescence polarization-based high-throughput assay.
Journal: Antimicrobial agents and chemotherapy
Published: July 19, 2024
Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery.
Journal: ACS infectious diseases
Published: October 31, 2023
Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum.
Journal: Microbiology spectrum
Published: December 19, 2022
Virtual Special Issue: Epigenetics 2022.
Journal: Journal of medicinal chemistry
Published: September 08, 2022
Virtual Special Issue: Epigenetics 2022.
Journal: ACS infectious diseases
Published: September 08, 2022
Virtual Special Issue: Epigenetics 2022.
Journal: ACS medicinal chemistry letters
Published: August 22, 2022
Virtual Special Issue: Epigenetics 2022.
Journal: ACS pharmacology & translational science
Published: August 22, 2022
Essential Bromodomain TcBDF2 as a Drug Target against Chagas Disease.
Journal: ACS infectious diseases
Published: April 28, 2022
Bromodomain factor 5 is an essential regulator of transcription in Leishmania.
Journal: Nature communications
Published: November 01, 2021
Last Updated: 09/26/2026